Register to join on Zoom

Intravenous Immune Globulin (IVIg)

A newly approved therapeutic option for the treatment of adult dermatomyositis

with Rohit Aggarwal, MD, MS

Tuesday, April 5, 2022, at 2 PM Eastern Time

(2 PM ET / 1 CT / 12 MT / 11 AM PT)

Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with a characteristic skin rash and progressive proximal muscle weakness. In this Zoom webinar, you will get an opportunity to learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The successful ProDERM Study resulted in the first and only FDA-approved IVIg therapy for DM in adults.

Myositis Support & Understanding and Octapharma USA are proud to co-sponsor this exciting educational program. We look forward to having you join us!

See the full PDF invite here.

About joining this webinar

REGISTRATION IS REQUIRED for this free webinar. Click the Register button above to get started. After registration, you will receive an email containing all of the information you need to join the webinar on the scheduled time and date. Be sure to check your spam and junk folders if you do not see the email.

Rohit Aggarwal, MD, MS

Professor of Medicine,
Medical Director, Arthritis and Autoimmunity Center;
Department of Medicine / Division of Clinical Immunology & Rheumatology
University of Pittsburgh Medical Center

Dr. Aggarwal is a professor of medicine at the University of Pittsburgh and medical director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center. He is the co-director of UPMC Myositis Center. His research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease. He is the past-chair of the medical advisory board of The Myositis Association (TMA) as well as past-chair of the scientific committee of IMACS.

Dr. Aggarwal is an established independent clinical investigator with significant funding from the NIH, foundations and industry, and currently leading several collaborations internationally with other key leaders in the world. He has maintained an extremely high publication record and received national and international recognition of his work. He continues to be a leader in disease criteria and outcomes measures in myositis as well as in clinical trials of novel therapeutic agents for myositis. He is currently the principal investigator or member of the steering committee for several international phase 2/3 clinical trials in the area of myositis and associated ILD. Dr. Aggarwal is also mentoring the future generation of rheumatologists with great success and attracting younger rheumatologists toward myositis research for the advancement of the field. Dr. Aggarwal lectures at various international conferences and promotes patient education through his YouTube channel.